Uncategorized Archives - Page 6 of 251

WednesdayOct 09, 2024 9:45 am

New York Cannabis and Hemp Convention at NYS Fairgrounds

The success of the NECANN 2023 convention has paved for a larger NECANN 2024 convention. The convention will be held at the spacious NYS Fairgrounds in Syracuse accommodating a mammoth number of traders, enthusiasts, growers, marketers, entrepreneurs, and investors from the cannabis and hemp spectrum. One of the most coveted cannabis conventions, NECANN events are known for offering the best educational, interactive and business platform for cannabis enthusiasts. They broaden the horizons of every region they visit, offering phenomenal opportunities to the local business community. This time, the NECANN event will be held in the Empire State on October 25-26,…

FridaySep 27, 2024 9:45 am

NY Cannabis Insider Completes Successful NY Conference

The NY Cannabis Insider conference was hosted at the Crowne Plaza, The Desmond Hotel, in Albany, New York, on September 25, 2024. The state’s premier cannabis event saw a great turnout of over 100 enthusiasts, entrepreneurs, marketers, traders, attorneys, and consultants, from throughout the cannabis industry. The entry ticket covered all access to the all-day conference, happy hour and lunch, entry to the vendor fair, and offered wonderful opportunity to connect directly with leaders in the cannabis industry. Select vendors arranged for complimentary consultation sessions for attendees. With evolutions imminent in the cannabis industry, the NY Cannabis Conference provided a…

ThursdaySep 26, 2024 9:45 am

420 Expo: New Jersey’s Largest Consumer Cannabis Convention Ends the Summer Season with 3-Days of Industry ‘Edutainment’; Announces Winners of the First-Ever Legal Statewide Cannabis Cup

The 420 Expo (https://www.420expo.com/) recently concluded its third annual three-day event series with over 14,000 cannabis enthusiasts making their way to the New Jersey Convention and Exposition Center, in Edison, September 13-15, 2024. Presented by Wakit Grinders (https://wakitgrinders.com), the B.Y.O.C. (bring your own cannabis) public event featured access to a large variety of cannabis-friendly vendors and dispensaries, cultivators, CBD businesses, accessories, and beverages, clothing and apparel, jewelry, art, food trucks, celebrity guests, glass blowers and lots of other brands and products. Guests had the opportunity to attend a variety of seminars and engage with canna-focused nonprofits and advocacy groups, as…

FridaySep 20, 2024 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires New CEO Amid Shift in Focus to Pharmaceutical Industry Collaboration and Operations

Lexaria, a global innovator in drug delivery platforms, announced the appointment of Richard Christopher as its new CEO, replacing Chris Bunka who will serve in his new capacity as Executive Strategic Advisor while remaining Chairman of the Board Lexaria also announced entering a Material Transfer Agreement with an undisclosed pharmaceutical industry partner, leading to speculation of which company has taken this formal step to get closer to Lexaria’s technology The company is focusing on this pharmaceutical industry collaboration and on investigations in cardiometabolic and GLP-1 sectors (alternative diabetes and obesity treatments), a huge sector that particularly needs its unmatched technology…

TuesdaySep 17, 2024 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Demonstrates Continued DehydraTECH(TM)-Liraglutide Performance with Ongoing GLP-1 Diabetes Animal Study

Lexaria, a global innovator in drug delivery platforms, is reporting on its eight-week body weight results from its WEIGHT-A24-1 ongoing animal study The study was made up of three main groups of formulations: DehydraTECH-processed CBD; semaglutide (including “Rybelsus(R)”) and liraglutide The DehydraTECH-CBD and DehydraTECH-liraglutide both outperformed Rybelsus(R), which was a surprise outcome. DehydraTECH-liraglutide posted a weight reduction of 4.74%, the most significant in the study For Lexaria, this continued outperformance of DehydraTECH-liraglutide is of particular interest, particularly since many third-party studies have shown semaglutide to be more than twice as effective as liraglutide in promoting weight loss As the study…

FridaySep 13, 2024 9:00 am

New York Cannabis Insider Conference: The State’s Premier Cannabis Event

Cannabis traders, entrepreneurs, growers, stakeholders, service providers, regulators, industry leaders, and investors, are invited to attend the state’s premier cannabis event at The Desmond Hotel in Albany, New York on Sept. 25. The NY Cannabis Insider Conference provides a major learning and networking platform to the New York cannabis industry. As the legal weed industry grows, the conference is designed to address the evolving issues of the industry. The live events at the conference allow participants to learn the licensing and regulatory policies, the latest technology resources and products, and a number of operational tips from stalwarts attending the event.…

ThursdaySep 12, 2024 9:00 am

Alternative Products Expo Arrives in Atlanta

The Alt Pro Expo, presented by Trinity Hemp, is coming to Atlanta on Oct. 10-12, 2024. Atlanta has a vibrant history with a legacy of smoke-shop culture. The southern city attracts retailers and buyers from neighboring cities, blending seamlessly into the new-age Alternative Products scene. Atlanta offers several recreational options to the attendees of the Expo. The Alternative Products Expo presents a dynamic platform for learning, exhibitions and collaborations in the Alternative Products industry. It brings together manufacturers, retailers, professionals, consumers, and enthusiasts, showcasing the latest products and services in the counterculture industry. The Alternative Products Expo in Atlanta will…

ThursdaySep 05, 2024 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Yields “Extremely Interesting” Results for DehydraTECH(TM) Liraglutide in Ongoing Diabetes Animal Study

Lexaria, a global innovator in drug delivery platforms, has just announced its 4-week and 8-week blood glucose results from its WEIGHT-A24-1 animal study Two formulations from the study posted outstanding performance, with each utilizing the company’s patented DehydraTECH(TM) technology DehydraTECH-liraglutide (Group H) and two DehydraTECH-CBD formulations (Groups A & B) posted blood sugar level reductions of 2.50%, 1.90%, and 1.53%, respectively These results build on the positive results from Lexaria’s 2023 DIAB-A22-1 animal study, which showed a 16.7% blood sugar concentration increase relative to baseline by day 56 for the obese control group that got no treatment Lexaria Bioscience (NASDAQ:…

ThursdayAug 29, 2024 10:30 am

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-901: A Promising New Candidate for Alzheimer’s Therapy

INM-901 oral formulation shows encouraging results in preclinical studies High bioavailability of INM-901 oral formulation was shown to provide similar drug concentration levels in the brain as intraperitoneal injection Oral delivery method offers advantages such as lower treatment costs, in comparison with intravenous delivery of large molecule antibody therapies The company is conducting further research including drug metabolism studies, dose ranging studies and pharmacokinetic studies InMed Pharmaceuticals (NASDAQ: INM), a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors, announced that its drug candidate INM-901 as an oral formulation will…

MondayAug 26, 2024 12:00 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Validates Technology’s Superiority, Moving Closer to a Share in the Global Diabetes Treatment Market

Lexaria, a global innovator in drug delivery platforms, just reported positive results from its applied research program conducted in collaboration with the National Research Council of Canada (“NRC”) The study’s objective was to examine the molecular properties of semaglutide, processed with its patented DehydraTECH(TM) technology, comparing it to Rybelsus(R), the commercially available alternative Lexaria’s DehydraTECH demonstrated that semaglutide can be efficiently released in a simulated gastric fluid environment, without the use of salcaprozate sodium (“SNAC”) ingredient chemistry This milestone moves the company closer to the diabetes treatment market, projected to hit $153.98 billion in value by 2032 Lexaria Bioscience (NASDAQ:…